• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13E3/A filed

    1/19/21 9:32:57 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care
    Get the next $RELV alert in real time by email
    SC 13E3/A 1 relv20210115_sc13e3a.htm SCHEDULE 13E3/A relv20210115_sc13e3a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13E-3/A

    (Rule 13e-100)

     

    (Amendment No. 3-Final Amendment)

     

    RULE 13E-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

     

    RELIV INTERNATIONAL, INC.

    (Name of the Issuer)

     

    RELIV INTERNATIONAL, INC.

    ROBERT L. MONTGOMERY

    STEPHEN M. MERRICK

    (Name of Person(s) Filing Statement)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    75952 R 209

    (CUSIP Number of Class of Securities)

     

    Ryan A. Montgomery

    Chief Executive Officer

    Reliv International, Inc.

    136 Chesterfield Industrial Blvd.

    Chesterfield, Missouri 63005

    (636) 537-9715

     

    (Name, address and telephone number of person authorized to receive notices and communications on behalf of the person(s) filing statement)

     

    with a copy to:

     

    Jude M. Sullivan

    Howard & Howard Attorneys PLLC

    200 S. Michigan Ave., Suite 1100

    Chicago, IL 60604

    (312) 372-4000

     

     


    This statement is filed in connection with (check the appropriate box):

     

    a.

    ☒

    The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act of 1934.

    b. ☐ The filing of a registration statement under the Securities Act of 1933.
    c. ☐ A tender offer.
    d. ☐ None of the above.

     

    Check the following box if the soliciting materials or information statement referred to in the checking box (a) are preliminary copies: ☐

     

    Check the following box if the filing is a final amendment reporting the results of the transaction:     ☒

     

     

     

     

    CALCULATION OF FILING FEE

     

    Transaction valuation*

    $2,521,841.25

    Amount of filing fee

    $275.13

     

    *

    For purposes of calculating the fee only. This amount assumes the aggregate cash payment of $2,521,841.25 (the “Total Consideration”) by the Company in lieu of issuing fractional shares immediately following the 1-for-2000 reverse stock split to holders of fewer than 2,000 shares of the Company’s common stock prior to the reverse stock split. The aggregate cash payment is equal to the product of the price of $3.75 per pre-split share and 672,491 pre-split shares, the estimated aggregate number of shares held by holders of less than 2,000 shares of the Company’s common stock. Pursuant to Rule 0-11(b)(1), the amount required to be paid with the filing of this Schedule 13E-3 equals .0001091 of the Total Consideration.

     

    ☒

    Check the box if any part of the fee is offset as provided by Rule 0-11(a) (2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

     

     

    Amount Previously Paid: $135.01    Form or Registration No.: Schedule 13E-3
    Filing Party: Reliv International, Inc.   Date Filed: October 22, 2020

     

     

    -2-

     

     

    RULE 13e-3 TRANSACTION STATEMENT

     

    INTRODUCTION

     

     

    This Amendment No. 3 amends and supplements the Rule 13e-3 Transaction Statement on Schedule 13E-3 (“Schedule 13E-3”), filed pursuant to Section 13(e) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), by Reliv International, Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “SEC”) on October 22, 2020, as previously amended and supplemented by Amendment No. 1 to the Schedule 13E-3 filed with the SEC on November 18, 2020 and Amendment No. 2 to the Schedule 13E-3 filed with the SEC on November 24, 2020. This Amendment No. 3 is being filed with the SEC pursuant to Rule 13e-3(d)(3) as a final amendment to the Schedule 13E-3 to report steps taken by the Company to effectuate the Transaction (as described below).

     

    On September 8, 2020, our Board of Directors (the "Board") approved amendments to our Certificate of Incorporation (the "Certificate of Incorporation") to effect a reverse stock split of our Common Stock followed immediately by a forward stock split of our Common Stock (the “Stock Split") and (ii) our receipt of written consents dated October 16, 2020, approving such amendments by stockholders holding 51.5% of the voting power of all of our stockholders entitled to vote on the matter as of August 26, 2020 (the "Record Date"). The resolutions adopted by the Board and the written consents of the stockholders gave us the authority to file Certificates of Amendment to the Certificate of Incorporation (the "Certificates of Amendment"). The Certificates of Amendment were filed with the Secretary of State of the State of Delaware on December 21 and 22, 2020, and became effective immediately thereafter (the "Effective Date"). As a result of the Stock Split, stockholders owning fewer than 2,000 shares of our Common Stock were cashed out at a price of $3.75 per share, and the holdings of all other stockholders will remain unchanged.

     

    The Stock Split is being undertaken as part of the Company’s plan to suspend its obligations to file periodic and current reports and other information with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Board determined that the costs of being a public reporting company outweigh the benefits thereof. The actions, including effecting the Stock Split, delisting our common stock from trading on the NASDAQ Stock Exchange, terminating the registration of our common stock under Sections 12(b) and 12(g) of the Exchange Act and suspending of our reporting obligations under Section 15(d) of the Exchange Act, are collectively referred to herein as the “Transaction.” After giving effect to the Transaction, we will no longer be subject to the reporting requirements under the Exchange Act or other requirements applicable to a public company, including requirements under the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) and the listing standards of any national securities exchange. However, we intend to maintain our existing internal controls and corporate governance framework.

     

    In connection with the consummation of the Transaction, the Company filed a Form 25 on December 21, 2020 to delist the Company’s common stock from the NASDAQ Stock Exchange. As a result, trading of the Company’s common stock was suspended on December 22, 2020 prior to the market opening. On January 19, 2021, the Company filed a Form 15 with the SEC certifying that it has less than 300 stockholders, which terminated the registration of the Company’s common stock under Section 12(g) of the Exchange Act.

     

    -3-

     

     

    SIGNATURE

     

     

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: January 19, 2021 

    RELIV INTERNATIONAL, INC. 

     

     

     

     

     

     

     

     

     

     

    By:

    /s/ Ryan A. Montgomery

     

     

     

    Ryan A. Montgomery

     

     

     

    Chief Executive Officer 

     

     

     

     
    Get the next $RELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RELV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RELV
    SEC Filings

    View All

    SEC Form 15-12G filed

    15-12G - RELIV INTERNATIONAL INC (0000768710) (Filer)

    1/19/21 9:42:44 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13E3/A filed

    SC 13E3/A - RELIV INTERNATIONAL INC (0000768710) (Subject)

    1/19/21 9:32:57 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care

    SEC Form 8 filed

    8-K - RELIV INTERNATIONAL INC (0000768710) (Filer)

    12/23/20 11:34:31 AM ET
    $RELV
    Major Pharmaceuticals
    Health Care

    $RELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Reliv International, Inc. Announces Update to its Reverse Stock Split Transaction and Plan to Delist from NASDAQ and Deregister its Common Stock

    CHESTERFIELD, Mo., Dec. 4, 2020 /PRNewswire/ -- Reliv International, Inc. (NASDAQ:RELV), a developer and marketer of nutritional supplements that promote optimal health, today announced an update to its plan to suspend its obligations to file periodic and current reports and other information with the U.S. Securities and Exchange Commission (the "Commission") under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and to delist its common stock from trading on the NASDAQ Stock Exchange as previously announced in a press release on October 19, 2020. December 21, 2020 will be the effective date of the Company's 1-for-2,000 reverse stock split (the "Reverse Split") of its

    12/4/20 4:15:00 PM ET
    $RELV
    Major Pharmaceuticals
    Health Care